Fangda Li

This paper develops a bacterial platform that combines enzyme/prodrug chemotherapy and immunotherapy to enhance antitumor responses with improved safety in a murine tumor model.

This study shows engineered E. coli expressing CXCL13 enhances bladder cancer immunotherapy when combined with PD-1 blockade by promoting tumor-specific antibody responses.

This study engineers probiotic E. coli to deliver neoantigen peptides, enhancing T cell immunity and reducing tumor growth in mice.

This paper develops a programmable probiotic encapsulation system using synthetic biology to enhance therapeutic delivery in mice by controlling bacterial immunogenicity and survivability.